Title: NeoPharm and LegoChem co-develop a novel anti-inflammary drug
Publication: inews / Hye Jeong Lim
Date: 21 June 2007
Summary
NeoPharm and LegoChem
signed an agreement on co-developing new PAR2 inhibitors. NeoPharm is investing $0.5 milion in
LegoChem, acquiring 3.46% of the equity, and is entitled to receive certain portion of royalties.
To view the full article
(in Korean), click here ▶
About
LegoChem Biosciences
LegoChem
Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to
discovering, developing, and commercializing innovative medicines by leveraging
our chemistry expertise to make conventional biologics targeted and more potent
for the benefit of patients with diseases of high unmet medical needs. We are
advancing sustainable pipelines in therapeutic areas in antibiotics,
anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug
conjugate (PDC).
|
|
IP : 106.243.208.*** 
|
